Trial · NCT07030426
Vaginal Estrogen for Improvement of Outcomes Following Pelvic Organ Prolapse Surgery
NCT07030426, Phase 3, Recruiting, Sarah Wozney
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Vaginal Estrogen for Improvement of Outcomes Following Pelvic Organ Prolapse Surgery. Trials, record NCT07030426. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07030426
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Vaginal Estrogen for Improvement of Outcomes Following Pelvic Organ Prolapse Surgery
- NCT number
- NCT07030426
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 180 participants, estimated
- Lead sponsor
- Sarah Wozney
- Conditions
- Pelvic Organ Prolapse (POP)
- Interventions
- Vaginal Estrogen - Twice Weekly, Vaginal Estrogen - Daily
- First posted
- 2025-06-22
- Last updated
- 2026-08-20
Source ClinicalTrials.gov
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Recruitment Rate | 12 months | For the primary feasibility outcome, the trial will be considered feasible if at least 75% of the target sample can be recruited in 12 months. |
| Secondary | Loss to Follow Up Rate - 6 months | 6 Months post surgery | Loss to follow up rates at each of the study end points measured as n/N (%). |
| Secondary | Loss to Follow Up Rate - 1 year | 1 year post surgery | Loss to follow up rates at each of the study end points measured as n/N (%). |
| Secondary | Loss to Follow Up Rate - 2 years | 2 years post surgery | Loss to follow up rates at each of the study end points measured as n/N (%). |
| Secondary | Patient Satisfaction - 6 weeks | 6 weeks post surgery | Patient satisfaction will be assessed using the Surgical Satisfaction Questionnaire (SSQ-8). This questionnaire measures satisfaction with the surgical procedure on a scale from 8 (most satisfied) to 40 (least satisfied). |
| Secondary | Patient Satisfaction - 6 months | 6 months post surgery | Patient satisfaction will be assessed using the Surgical Satisfaction Questionnaire (SSQ-8). This questionnaire measures satisfaction with the surgical procedure on a scale from 8 (most satisfied) to 40 (least satisfied). |
| Secondary | GSM Symptoms - 6 weeks | 6 weeks post surgery | GSM symptoms will be assessed using the Visual Analog Scale (VAS) on GSM symptoms. It assesses 5 symptoms (dryness, itching, burning, dyspareunia, and dysuria) on a scale from 0 - 10, from no symptoms to severe symptoms. |
| Secondary | GSM Symptoms - 6 months | 6 weeks post surgery | GSM symptoms will be assessed using the Visual Analog Scale (VAS) on GSM symptoms. It assesses 5 symptoms (dryness, itching, burning, dyspareunia, and dysuria) on a scale from 0 - 10, from no symptoms to severe symptoms. |
| Secondary | GSM Symptoms - 1 year | 1 year post surgery | GSM symptoms will be assessed using the Visual Analog Scale (VAS) on GSM symptoms. It assesses 5 symptoms (dryness, itching, burning, dyspareunia, and dysuria) on a scale from 0 - 10, from no symptoms to severe symptoms. |
| Secondary | GSM Symptoms - 2 years | 2 years post surgery | GSM symptoms will be assessed using the Visual Analog Scale (VAS) on GSM symptoms. It assesses 5 symptoms (dryness, itching, burning, dyspareunia, and dysuria) on a scale from 0 - 10, from no symptoms to severe symptoms. |
1 to 10 of 19Source ClinicalTrials.gov
See all 19 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07030426
GET https://conductscience.org/api/trials/v1/NCT07030426/registered